Research Paper Volume 12, Issue 21 pp 21706—21729
Puerarin alleviates osteoporosis in the ovariectomy-induced mice by suppressing osteoclastogenesis via inhibition of TRAF6/ROS-dependent MAPK/NF-κB signaling pathways
Figure 9. Puerarin inhibits RANKL-induced osteoclast differentiation by suppressing the NF-κB and MAPK signaling pathways. (A) Representative western blot images show the levels of p-IκBα, IκBα, NF-κB-p65, and p-NF-κB-p65 at 0, 10, 20, 30 and 60 mins in the RANKL- andRANKL+puerarin-treated RAW264.7 cells. (B–C) The histograms show the relative levels of p-IκBα and p-NF-κB proteins at 0, 10, 20, 30 and 60 min in the RANKL-, and RANKL+puerarin-treated RAW264.7 cells. Note: n=3 per group; *P <0.05 **P <0.01 vs. the RANKL-induced group. (D) Representative western blot images show the levels of ERK, p-ERK, JNK, p-JNK, P38 and p-P38 MAP kinases at 0, 10, 20, 30 and 60 min in the RANKL-, and RANKL+puerarin-treated RAW264.7 cells. (E–G) The histograms show the relative levels of the p-ERK, p-JNK, and p-p38 proteins at 0, 10, 20, 30 and 60 min in the RANKL-, and RANKL+puerarin-treated RAW264.7 cells. Note: n=3 per group, *P <0.05, **P <0.01 vs. the RANKL-induced group at the same time point.